2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Jonathan L. Halperin, MD, FACC, FAHA, Chair Glenn N. Levine, MD, FACC, FAHA, Chair-Elect Sana M. Al-Khatib, MD, MHS, FACC, FAHA Kim K. Birtcher, PharmD, MS, AACC Biykem Bozkurt, MD, PhD, FACC, FAHA Ralph G. Brindis, MD, MPH, MACC, FAHA Joaquin E. Cigarroa, MD, FACC Lesley H. Curtis, PhD,

[1]  N. Deshpande,et al.  Prasugrel versus clopidogrel for acute coronary syndromes without revascularization , 2013 .

[2]  Patrick Hunziker,et al.  Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. , 2006, Journal of the American College of Cardiology.

[3]  B. Gersh.  Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents , 2011 .

[4]  Harlan M Krumholz,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physi , 2012, Journal of the American College of Cardiology.

[5]  C. Jackevicius,et al.  Use of Aspirin and Clopidogrel After Coronary Artery Bypass Graft Surgery , 2012, The Annals of pharmacotherapy.

[6]  M. Fredrikson,et al.  To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. , 2010, British journal of anaesthesia.

[7]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.

[8]  D. Angiolillo,et al.  Management of Antiplatelet and Anticoagulant Therapy in Patients With Atrial Fibrillation in the Setting of Acute Coronary Syndromes or Percutaneous Coronary Interventions , 2014, Circulation. Cardiovascular interventions.

[9]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[10]  V. Fuster,et al.  Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. , 1984, The New England journal of medicine.

[11]  P. Erwin,et al.  Dual Anti‐platelet Therapy After Coronary Artery Bypass Grafting: Is There Any Benefit? A Systematic Review and Meta‐Analysis , 2013, Journal of cardiac surgery.

[12]  A. Raizner,et al.  Catastrophic outcomes of noncardiac surgery soon after coronary stenting. , 2000, Journal of the American College of Cardiology.

[13]  Chang-qing Gao,et al.  Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting. , 2009, The Annals of thoracic surgery.

[14]  Jeroen J. Bax,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2012 .

[15]  S. Yusuf,et al.  Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.

[16]  Jeffrey L. Anderson,et al.  The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[17]  B. Meyers,et al.  The American Association for Thoracic Surgery , 2016 .

[18]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[19]  R. Ferrari,et al.  Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). , 2014, Journal of the American College of Cardiology.

[20]  T. Wagner,et al.  Effect of clopidogrel use post coronary artery bypass surgery on graft patency. , 2014, The Annals of thoracic surgery.

[21]  Richard A. Goodman,et al.  AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. , 2014, Circulation.

[22]  M. Hawn,et al.  The incremental risk of noncardiac surgery on adverse cardiac events following coronary stenting. , 2014, Journal of the American College of Cardiology.

[23]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[24]  H. Wijeysundera,et al.  Risk of Elective Major Noncardiac Surgery After Coronary Stent Insertion: A Population-Based Study , 2012, Circulation.

[25]  G. Hillis,et al.  Platelet activation, myocardial ischemic events and postoperative non‐response to aspirin in patients undergoing major vascular surgery , 2007, Journal of thrombosis and haemostasis : JTH.

[26]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[27]  Deepak L. Bhatt,et al.  Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding , 2009, Annals of Internal Medicine.

[28]  W Klein,et al.  Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). , 2004, European heart journal.

[29]  E. Steyerberg,et al.  Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. , 2012, European heart journal.

[30]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[31]  Deepak L. Bhatt,et al.  Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.

[32]  Seung‐Jung Park,et al.  Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. , 2015, Journal of the American College of Cardiology.

[33]  Giuseppe Biondi-Zoccai,et al.  Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.

[34]  T. Henry,et al.  Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction: Insights From the Treatment with ADP Receptor Inhibitors Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study , 2015, Circulation.

[35]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[36]  R. D'Agostino,et al.  Causes of late mortality with dual antiplatelet therapy after coronary stents. , 2015, European heart journal.

[37]  I. Liu,et al.  Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions. , 2008, Journal of the American College of Cardiology.

[38]  F. R. Zadik.  FRACTURE OF THE FEMORAL NECK. , 1964, Lancet.

[39]  G. Lip,et al.  Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials , 2015, BMJ : British Medical Journal.

[40]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[41]  E. Vicaut,et al.  Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial , 2014, The Lancet.

[42]  A. Aytaç,et al.  Postoperative clopidogrel improves mid-term outcome after off-pump coronary artery bypass graft surgery: a prospective study. , 2006, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[43]  Sunil V. Rao,et al.  Baseline Risk of Major Bleeding in Non–ST-Segment–Elevation Myocardial Infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Bleeding Score , 2009, Circulation.

[44]  P. Serruys,et al.  Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents: A Prospective Cohort Study , 2012, Circulation.

[45]  Tom Adriaenssens,et al.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial , 2013, The Lancet.

[46]  Shengshou Hu,et al.  Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. , 2010, Journal of the American College of Cardiology.

[47]  Samin K. Sharma,et al.  Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. , 2011, Journal of the American College of Cardiology.

[48]  S. Vernadakis,et al.  Alterations of hemostasis after laparoscopic and open surgery , 2007, Hematology.

[49]  Fredrik Folke,et al.  Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.

[50]  M. Price,et al.  Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. , 2012, JAMA.

[51]  M. Pencina,et al.  Frequency of major noncardiac surgery and subsequent adverse events in the year after drug-eluting stent placement results from the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry. , 2010, JACC. Cardiovascular interventions.

[52]  R. Haaverstad,et al.  Effect of clopidogrel on midterm graft patency following off-pump coronary revascularization surgery. , 2006, The heart surgery forum.

[53]  Jeffrey L. Anderson,et al.  The Evolution and Future of ACC/AHA Clinical Practice Guidelines: A 30-Year Journey A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[54]  M. Togni,et al.  Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. , 2015, Journal of the American College of Cardiology.

[55]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[56]  Laura Mauri,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Circulation.

[57]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[58]  Thomas E. Moritz,et al.  Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. , 1988, Circulation.

[59]  M. Hawn,et al.  Association of Coronary Stent Indication With Postoperative Outcomes Following Noncardiac Surgery. , 2016, JAMA surgery.

[60]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[61]  P. R. R. Ecurrent,et al.  EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .

[62]  S. Werns.  Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study , 2010 .

[63]  J. Wójcik,et al.  6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. , 2015, Journal of the American College of Cardiology.

[64]  J. Cigarroa,et al.  Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[65]  Werner Klein,et al.  Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) , 2003 .

[66]  P. Mody,et al.  Ticagrelor Compared With Clopidogrel by Geographic Region in the Platelet Inhibition and Patient , 2011 .

[67]  Baris Gencer,et al.  ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation , 2011 .

[68]  C. Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. , 2011, Journal of the American College of Cardiology.

[69]  Walter Desmet,et al.  ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.

[70]  Biykem Bozkurt,et al.  2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[71]  S. de Servi,et al.  Management of patients with recently implanted coronary stents on dual antiplatelet therapy who need to undergo major surgery , 2011, Journal of thrombosis and haemostasis : JTH.

[72]  C. Bode,et al.  Triple antithrombotic therapy in cardiac patients: more questions than answers. , 2014, European heart journal.

[73]  F. Verheugt,et al.  Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. , 2009, Journal of the American College of Cardiology.

[74]  D. Andreini,et al.  COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY VERSUS STRESS CARDIAC MAGNETIC RESONANCE FOR THE MANAGEMENT OF SYMPTOMATIC REVASCULARIZED PATIENTS: A COST EFFECTIVENESS STUDY (STRATEGY STUDY) , 2016 .

[75]  J. Hirsh,et al.  Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[76]  H. Schunkert,et al.  Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation: The ISAR-TRIPLE Trial. , 2015, Journal of the American College of Cardiology.

[77]  H. Watson,et al.  Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures , 2008, British journal of haematology.

[78]  Laura A. Levit,et al.  Finding what works in health care : standards for systematic reviews , 2011 .

[79]  C. Varenhorst,et al.  Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR. , 2014, Journal of the American College of Cardiology.

[80]  R. Califf,et al.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. , 1996, Journal of the American College of Cardiology.

[81]  S. Saito,et al.  Efficacy and Safety of a Novel Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent: The EVOLVE II Randomized Trial , 2015, Circulation. Cardiovascular interventions.

[82]  S. Scott,et al.  Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. , 2011, JAMA.

[83]  S. Pocock,et al.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. , 1999, The New England journal of medicine.

[84]  M. Bell,et al.  Timing of coronary stent thrombosis in patients treated with ticlopidine and aspirin. , 1999, The American journal of cardiology.

[85]  S. Yusuf,et al.  Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. , 2008, European heart journal.

[86]  P. Berger,et al.  Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. , 2003, Journal of the American College of Cardiology.

[87]  H. Suryapranata,et al.  First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients , 2014, Open Heart.

[88]  David B Matchar,et al.  Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. , 2007, JAMA.

[89]  M. Jeong,et al.  Duration of dual antiplatelet therapy after implantation of drug-eluting stents. , 2010, The New England journal of medicine.

[90]  F. Verheugt,et al.  Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review. , 2014, Journal of the American College of Cardiology.

[91]  Charles J. Kahi,et al.  ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2010, The American Journal of Gastroenterology.

[92]  S. Yusuf,et al.  Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.

[93]  H. Suryapranata,et al.  Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis , 2013, BMJ.

[94]  S. Wild,et al.  Previous Coronary Stent Implantation and Cardiac Events in Patients Undergoing Noncardiac Surgery , 2010, Circulation. Cardiovascular interventions.

[95]  S. Yusuf,et al.  Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. , 2010, American heart journal.

[96]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[97]  Deepak L. Bhatt,et al.  ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[98]  C. Vosa,et al.  Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study , 2012, Heart.

[99]  S. Steinhubl,et al.  Aspirin following PCI: too much of a good thing? , 2008, European heart journal.

[100]  Marc P. Bonaca,et al.  Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. , 2015, European heart journal.

[101]  S. Yusuf,et al.  Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial , 2010, The Lancet.

[102]  V. Kocka,et al.  Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’ , 2014, European heart journal.

[103]  Marc P. Bonaca,et al.  Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. , 2016, European heart journal.

[104]  A. Tsiatis,et al.  The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. , 2004, Journal of the American College of Cardiology.

[105]  P. Serruys,et al.  Stent Thrombosis With Everolimus-Eluting Stents: Meta-Analysis of Comparative Randomized Controlled Trials , 2012, Circulation. Cardiovascular interventions.

[106]  A. Hartz,et al.  Aspirin use and survival after coronary bypass surgery. , 1992, American heart journal.

[107]  D. Whellan,et al.  Aspirin and clopidogrel use in the early postoperative period following on-pump and off-pump coronary artery bypass grafting. , 2009, The Journal of thoracic and cardiovascular surgery.

[108]  J. Spertus,et al.  Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.

[109]  Antonio Colombo,et al.  Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.

[110]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[111]  C. Cannon,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial , 2011, BMJ : British Medical Journal.

[112]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[113]  J. Ornato,et al.  ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation , 2007, Circulation.

[114]  P. Weber,et al.  IMPROVED AORTOCORONARY BYPASS PATENCY BY LOW-DOSE ASPIRIN (100 mg DAILY) Effects on Platelet Aggregation and Thromboxane Formation , 1984, The Lancet.

[115]  Deepak L. Bhatt,et al.  ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use , 2010, The American Journal of Gastroenterology.

[116]  M. Kazatchkine,et al.  Evaluation of Thromboxane Production and Complement Activation During Myocardial Ischemia in Patients With Angina Pectoris , 1991, Circulation.

[117]  F. Eberli,et al.  Polymer-free Drug-Coated Coronary Stents. , 2016, The New England journal of medicine.

[118]  S. Greenfield,et al.  COMMITTEE ON STANDARDS FOR DEVELOPING TRUSTWORTHY CLINICAL PRACTICE GUIDELINES , 2011 .

[119]  J. Fajadet,et al.  Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. , 2012, Journal of the American College of Cardiology.

[120]  Donna K Arnett,et al.  AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. , 2014, Journal of the American College of Cardiology.

[121]  C. Held,et al.  Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery. , 2012, Journal of the American College of Cardiology.

[122]  T. Lüscher,et al.  Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding? , 2015, European heart journal.

[123]  Antonio Colombo,et al.  Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study , 2013, The Lancet.

[124]  P. Kirchhof,et al.  Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association , 2014, European heart journal.

[125]  B. Rangan,et al.  Outcomes of a preoperative "bridging" strategy with glycoprotein IIb/IIIa inhibitors to prevent perioperative stent thrombosis in patients with drug-eluting stents who undergo surgery necessitating interruption of thienopyridine administration. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[126]  L. Køber,et al.  Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. , 2011, Journal of the American College of Cardiology.

[127]  L. Mauri,et al.  Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis , 2015, The Lancet.

[128]  S. de Servi,et al.  Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. , 2010, British journal of anaesthesia.

[129]  A. Jacobs,et al.  Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. , 2015, Journal of the American College of Cardiology.

[130]  E. Vicaut,et al.  Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. , 2015, European heart journal.

[131]  Peter K. Smith,et al.  Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. , 2012, Journal of the American College of Cardiology.

[132]  M. Jeong,et al.  Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study , 2012, Circulation.

[133]  W. Cheong,et al.  Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial. , 2015, Journal of the American College of Cardiology.

[134]  E. Antman,et al.  Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial , 2009, The Lancet.

[135]  Volkmar Falk,et al.  Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I , 2022 .

[136]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[137]  A. Rabinstein.  Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial , 2008 .

[138]  S. Pocock,et al.  A risk score to predict bleeding in patients with acute coronary syndromes. , 2010, Journal of the American College of Cardiology.

[139]  F. Eberli,et al.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2008, The Lancet.

[140]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[141]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[142]  Deepak L. Bhatt,et al.  Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. , 2015, Journal of the American College of Cardiology.

[143]  D. Baim,et al.  Stent Thrombosis in the Modern Era: A Pooled Analysis of Multicenter Coronary Stent Clinical Trials , 2001, Circulation.

[144]  Deepak L. Bhatt,et al.  Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. , 2013, JAMA.

[145]  B. Gersh.  Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial , 2009 .

[146]  D. Schroeder,et al.  Time and Cardiac Risk of Surgery after Bare-metal Stent Percutaneous Coronary Intervention , 2008, Anesthesiology.

[147]  T. Henry,et al.  THE ASSOCIATION OF DISCHARGE ASPIRIN DOSE AND OUTCOMES IN ACUTE MYOCARDIAL INFARCTION: INSIGHTS FROM THE TRANSLATE-ACS STUDY , 2013 .

[148]  A. Kotsia,et al.  Outcomes of preoperative bridging therapy for patients undergoing surgery after coronary stent implantation: A weighted meta‐analysis of 280 patients from eight studies , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[149]  G. Guyatt,et al.  Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement , 2015, Annals of Internal Medicine.

[150]  J. Tardif,et al.  Aspirin Plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting: The Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trial , 2010, Circulation.

[151]  Deepak L. Bhatt,et al.  Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. , 2005, The American journal of cardiology.

[152]  L. Shaw,et al.  ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[153]  L. Neyses,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[154]  X. Álvarez,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events , 2007 .

[155]  G. Rücker,et al.  Low‐dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta‐analysis , 2005, Journal of internal medicine.

[156]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[157]  G. Davı̀,et al.  Clinical pharmacology of platelet cyclooxygenase inhibition. , 1985, Circulation.

[158]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[159]  C. Cannon,et al.  Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention: A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis , 2010, Circulation.

[160]  S. Achenbach,et al.  Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting. , 2013, The American journal of cardiology.

[161]  Stent Thrombosis in the Modern Era A Pooled Analysis of Multicenter Coronary Stent Clinical Trials , 2001 .

[162]  B. Lewis,et al.  Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. , 2005, JAMA.

[163]  M. Hawn,et al.  Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. , 2013, JAMA.

[164]  L. Køber,et al.  Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data , 2009, The Lancet.

[165]  PubMed Id.  ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013 .

[166]  P. Teirstein,et al.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. , 2015, The New England journal of medicine.

[167]  V. Fuster,et al.  A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. , 1982, The New England journal of medicine.

[168]  Deepak L. Bhatt,et al.  Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting , 2011, Thrombosis and Haemostasis.

[169]  Samin K. Sharma,et al.  Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. , 2015, Journal of the American College of Cardiology.

[170]  Janet S. Wright,et al.  2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesi , 2011, Journal of the American College of Cardiology.

[171]  Y. Jang,et al.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). , 2012, Journal of the American College of Cardiology.

[172]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[173]  R. de Caterina,et al.  Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis , 2017, European heart journal. Acute cardiovascular care.

[174]  J. Marchesini,et al.  Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting: A Randomized Multicenter Trial , 2012, Circulation.

[175]  S. Yusuf,et al.  Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial , 2013, Circulation.

[176]  M. Krucoff,et al.  Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. , 2016, JACC. Cardiovascular interventions.

[177]  M. Jeong,et al.  Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: A Randomized, Controlled Trial , 2014, Circulation.

[178]  Timothy J Gardner,et al.  Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American D , 2007, Circulation.

[179]  L. Mauri,et al.  Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). , 2015, The American journal of cardiology.

[180]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.